Clinical significance of serum levels of osteoproteherin and sclerostin in assessment of vascular calcification in chronic kidney disease stage 3–5

Clinical significance of serum levels of osteoproteherin and sclerostin in assessment of vascular calcification in chronic kidney disease stage 3–5

Aim. To clarify the mechanisms of the effect of osteoprotegerin (OPG) and sclerostin on vascular calcification and the state of the cardiovascular system in chronic kidney disease (CKD). Materials and methods. A total of 110 patients aged 18 to 65 years with CKD stages 35D were examined. OPG, scl...

Full description

Bibliographic Details
Main Authors:	Fatima U. Dzgoeva, Oleg V. Remizov, Victoria Kh. Botcieva, Victoria G. Goloeva, Nina G. Malakhova, Zarina R. Ikoeva
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2022-08-01
Series:	Терапевтический архив
Subjects:	chronic kidney disease osteoprotegerin sclerostin cardiovascular calcification remodeling of the heart and aorta
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/109609/83868

Similar Items

Clinical significance of uremic toxin indoxyl sulfate and inflammation in the development of vascular calcification and cardiovascular complications in stage C3–C5D chronic kidney disease
by: Fatima U. Dzgoeva, et al.
Published: (2023-08-01)

Serum sclerostin in vascular calcification in CKD: a meta-analysis
by: Yan Lin, et al.
Published: (2023-12-01)

The Role of Sclerostin in Bone and Ectopic Calcification
by: Annelies De Maré, et al.
Published: (2020-04-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
by: F. F. Rija, et al.
Published: (2021-10-01)

Sclerostin and Vascular Pathophysiology
by: Antonino Catalano, et al.
Published: (2020-07-01)

Study of serum sclerostin levels and its role in vascular calcification in patients with chronic kidney disease
by: Ahmed R Elarbagy, et al.
Published: (2019-01-01)

Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction
by: Xing Shui, et al.
Published: (2022-05-01)

Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients
by: Alper Kirkpantur, et al.
Published: (2016-01-01)

Sclerostin, vascular risk factors, and brain atrophy in excessive drinkers
by: Candelaria Martín-González, et al.
Published: (2023-02-01)

Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients
by: Tarek Z. El Baz, et al.
Published: (2017-06-01)

Arterial stiffness, vascular calcification and osteoporosis — common mechanisms of interaction (literature review)
by: O.I. Nishkumay, et al.
Published: (2022-06-01)

Sclerostin Modulation Holds Promise for Dental Indications
by: Mohamed G. Hassan, et al.
Published: (2018-11-01)

Association of sclerostin with cardiovascular events and mortality in dialysis patients
by: Yun Zou, et al.
Published: (2020-01-01)

Positive and Negative Regulators of Sclerostin Expression
by: Rina Iwamoto, et al.
Published: (2022-04-01)

Serum Osteoprotegerin level and the extent of cardiovascular calcification in haemodialysis patients
by: Waleed Ammar, et al.
Published: (2014-03-01)

A Prospective Cohort Study Showing No Association Between Serum Sclerostin Level and Mortality in Maintenance Hemodialysis Patients
by: Madoka Sato, et al.
Published: (2018-06-01)

Sclerostin is involved in osteogenic transdifferentiation of vascular smooth muscle cells in chronic kidney disease-associated vascular calcification with non-canonical Wnt signaling
by: Qiong Xiao, et al.
Published: (2022-12-01)

Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
by: Aoki Atsushi, et al.
Published: (2013-01-01)

Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet
by: Magnus Bäck, et al.
Published: (2019-01-01)

Bone markers and cardiovascular risk in type 2 diabetes patients
by: Sabine R. Zwakenberg, et al.
Published: (2018-03-01)

Association Between Risk Factors Including Bone-Derived Biomarkers and Aortic Arch Calcification in Maintenance Hemodialysis Patients
by: Kosaku Nitta, et al.
Published: (2018-10-01)

Drug discovery of sclerostin inhibitors
by: Sifan Yu, et al.
Published: (2022-05-01)

Sclerostin - a potential new marker of exercise influence on vascular calcification and mineral and bone disorder in hemodialysed adults
by: Agnieszka Turon-Skrzypinska, et al.
Published: (2019-12-01)

Biomarkers of vascular calcification: their relationship with diseases of the cardiovascular system and their importance in clinical practice
by: N. A. Maslatsov, et al.
Published: (2021-06-01)

Antitumor Effect of Sclerostin against Osteosarcoma
by: Hirokazu Ideta, et al.
Published: (2021-11-01)

Low serum Klotho level as a predictor of calcification of the heart and blood vessels in patients with CKD stages 2–5D
by: Ludmila Yu. Milovanova, et al.
Published: (2020-07-01)

Predictive Value of Measures of Vascular Calcification Burden and Progression for Risk of Death in Incident to Dialysis Patients
by: Antonio Bellasi, et al.
Published: (2021-01-01)

Sclerostin antibodies as novel anabolic therapy for osteoporosis
by: Elizaveta O. Mamedova, et al.
Published: (2019-04-01)

Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans
by: Sylvia Thiele, et al.
Published: (2019-07-01)

Bone status and aortic calcifications in chondrocalcinosis patients
by: Vele Paulina, et al.
Published: (2020-04-01)

Expression of sclerostin in alveolar bone remodeling of ovariectomized rats
by: GUO Ying, et al.
Published: (2020-12-01)

Associations between Sclerostin and Anthropometric and Metabolic Parameters in Children and Adolescents
by: Shin-Hee Kim, et al.
Published: (2021-09-01)

Biochemical markers of atherosclerotic plaque calcification
by: N. A. Maslatsov, et al.
Published: (2019-12-01)

Anti-Sclerostin Antibodies in Osteoporosis and Other Bone Diseases
by: Stéphanie Fabre, et al.
Published: (2020-10-01)

The roles of sclerostin and irisin on bone and muscle of orchiectomized rats
by: Bing-na Zhou, et al.
Published: (2022-12-01)

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis
by: Michalis Spartalis, et al.
Published: (2023-02-01)

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review
by: Venkitachalam Ramanarayanan, et al.
Published: (2022-12-01)

The role of sclerostin and PGC-1 alpha in the pathogenesis of osteoporosis
by: Armine V. GRIGORYAN, et al.
Published: (2020-06-01)

Biomechanical Properties of the Aortic Wall: Changes during Vascular Calcification
by: Jinwen Zhou, et al.
Published: (2023-01-01)

Sclerostin as Regulatory Molecule in Vascular Media Calcification and the Bone–Vascular Axis
by: Annelies De Maré, et al.
Published: (2019-07-01)